HPR24 Critical Analysis on Time-to-Reimbursement of Rare Disease Drugs: The Italian Case (AIFA Commissions 2018-2022)

Autor:	P Raimondo, D Giorgio, R Ravasio, E Leonetti, F Luccini
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S236
ISSN:	1098-3015
DOI:	10.1016/j.jval.2022.09.1156
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::276da6211527941ccd37909c6c072e9a https://doi.org/10.1016/j.jval.2022.09.1156 Zobrazit plný text záznamu Full Text from ScienceDirect